Welcome to our dedicated page for MATN news (Ticker: MATN), a resource for investors and traders seeking the latest updates and insights on MATN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MATN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MATN's position in the market.
Mateon Therapeutics Inc. (OTCQB:MATN) has received regulatory approval from Korea's Ministry of Food and Drug Safety for a Phase 1b clinical trial of its OT-101/IL-2 combination targeting solid cancers. This trial aims to confirm the safety and efficacy of OT-101 in collaboration with Clinigen Group and Autotelic BIO. OT-101 holds orphan drug designation for several cancers and a Rare Pediatric Designation for diffuse intrinsic pontine glioma. The drug has shown robust efficacy in previous trials and is being explored for its potential against COVID-19.
Mateon Therapeutics (OTCQB:MATN) has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients, achieving a target of 18 patients in each cohort. This study evaluates the safety and efficacy of OT-101 in treating COVID-19. Initial results indicate no acute adverse events related to OT-101. The company plans to expand the trial after thorough data assessment. OT-101 is an antisense therapeutic targeting TGF-β, which is linked to viral replication and severe COVID-19 symptoms, potentially offering a treatment approach amidst rising variants in Latin America.
Mateon Therapeutics (OTCQB: MATN) announced the publication of a pivotal clinical study on PulmoHeal™, an adjunct therapy for COVID-19. Results showed improved recovery rates across various standard of care protocols. The study indicated that PulmoHeal™ is also effective against multiple SARS-CoV-2 variants, reinforcing its broad-spectrum antiviral potential. The publication is significant as it highlights the therapeutic's role amidst rising COVID-19 variants. An expert panel discussion is scheduled for March 5, 2021, to further address PulmoHeal™.
Mateon Therapeutics (OTCQB:MATN) and Windlas Biotech have launched PulmoHeal™, an innovative respiratory wellness solution in India, targeting the 100 million people struggling with respiratory issues. PulmoHeal™ combines a drug supplement, a mobile AI app for health monitoring, and a post-marketing survey to enhance patient care and data collection. The drug, containing artemisinin, has shown significant efficacy against COVID-19 in clinical studies. Available through major online platforms, this comprehensive approach aims to empower patients and alleviate healthcare burdens.
Mateon Therapeutics (OTCQB:MATN) has announced a global partnership with the Chopra Foundation to advance research and development of its COVID-19 therapeutic brands, PulmoHeal™ and ARTIVeda™. The collaboration aims to leverage Ayurvedic medicine in treating infectious diseases, with a focus on integrating these therapies into patient care platforms. Mateon has completed patient randomization for its ARTI-19 trial in India and expects final data analysis in March 2021, with potential plans for Emergency Use Authorization to follow.
Mateon Therapeutics (OTCQB:MATN) announced approval from Argentina’s regulatory agency to commence a Phase 2 clinical trial for OT-101, a TGF-β antisense therapy targeting COVID-19. This trial aims to evaluate OT-101's safety and efficacy in two cohorts: patients with mild to moderate disease and those with severe disease requiring mechanical ventilation. The study will enroll 72 patients across multiple centers, with primary endpoints based on clinical improvement scores assessed at Day 14. CEO Dr. Vuong Trieu highlighted the urgent need for innovative COVID-19 treatments following setbacks in existing therapies.
Mateon Therapeutics (OTCQB: MATN) announced that Dr. Vuong Trieu will present clinical updates on COVID-19 trials at the Meridian Clinical Trials Summit on November 2-3, 2020, in San Francisco. The presentation will cover the challenges of conducting COVID-19 research in a competitive landscape. Mateon is conducting the ARTI-19 trial in India, evaluating Artemisinin for COVID-19 treatment compared to standard care, with safety and efficacy as key endpoints. The company aims to leverage its expertise in oncology to enhance treatment outcomes.
Mateon Therapeutics (OTCQB: MATN) announced that Dr. Vuong Trieu will present a company overview at the BIO Investor Forum Digital from October 13-15, 2020. The presentation will be available on demand. Mateon is advancing ArtiShieldTM, currently in Phase IV trials (ARTI-19) involving 3000 patients to assess its efficacy against COVID-19. The active ingredient, artemisinin, demonstrated strong in vitro results against SARS-CoV-2. Top-line data is expected by the end of Q4 2020. The company aims to improve treatment outcomes for cancer patients and has a focus on pediatric cancers.
Mateon Therapeutics (OTCQB: MATN) announced the enrollment of the first patient in its Phase IV study ARTI-19, aimed at evaluating ArtiShield for COVID-19 treatment. The trial, which has regulatory approval in India, aims to register 3,000 patients, with top-line results expected by the end of 4Q20. Windlas Biotech is conducting the trial across several centers in India. The study compares ArtiShield with standard of care to assess safety and efficacy. India's COVID-19 crisis remains severe, with over 6.7 million cases reported.
